Table 3 EQ-5D dimension score frequency at study baseline and end of cycle 3 (FAS)
From: Quality of life in subjects with upper- and lower-limb spasticity treated with incobotulinumtoxinA
Dimension | Visit | N | Nobs | Frequency, n (%) subjects | ||
|---|---|---|---|---|---|---|
1 Normal condition | 2 Moderate impairment | 3 Severe impairment | ||||
Mobility | Baseline | 155 | 155 | 12 (7.7) | 139 (89.7) | 4 (2.6) |
End of injection cycle 3 | 140 | 137 | 23 (16.4) | 112 (80.0) | 2 (1.4) | |
Self-care | Baseline | 155 | 155 | 30 (19.4) | 96 (61.9) | 29 (18.7) |
End of injection cycle 3 | 140 | 137 | 33 (23.6) | 93 (66.4) | 11 (7.9) | |
Usual activities | Baseline | 155 | 155 | 11 (7.1) | 113 (72.9) | 31 (20.0) |
End of injection cycle 3 | 140 | 137 | 22 (15.7) | 103 (73.6) | 12 (8.6) | |
Pain/discomfort | Baseline | 155 | 155 | 53 (34.2) | 85 (54.8) | 17 (11.0) |
End of injection cycle 3 | 140 | 137 | 72 (51.4) | 60 (42.9) | 5 (3.6) | |
Anxiety/depression | Baseline | 155 | 155 | 72 (46.5) | 69 (44.5) | 14 (9.0) |
End of injection cycle 3 | 140 | 137 | 82 (58.6) | 53 (37.9) | 2 (1.4) | |